60186-14-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Difluoro-3-nitropyridine is used as a key reactant in the synthesis of AMP579, a novel adenosine A1/A2 receptor agonist. 4-difluoro-3-nitropyridine has potential applications in the treatment of various diseases and conditions, such as neuroprotection, inflammation, and cardiovascular disorders, due to its ability to modulate adenosine receptor signaling pathways.
Additionally, 4-difluoro-3-nitropyridine can be utilized in the development of other bioactive molecules and drug candidates, given its reactivity and compatibility with various chemical transformations. Its presence in the molecular structure can impart unique properties and activities, making it a valuable building block in medicinal chemistry and drug discovery efforts.

Upstream product

• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 2751-90-8 tetraphenylphosphonium bromide 

Downstream Products

• 280756-72-1 [3aR-[3aα,4α,6a(R*),6aα]]-6-[4-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3-nitropyrid-2-ylamino] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 280756-73-2 [3aR-[3aα,4α,6a(R*),6aα]]-6-[4-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3-aminopyrid-2-ylamino] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 313268-73-4 [3aR-[3aα,4α,6a(R*),6aα]]-6-[7-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3H-imidazo(4,5-b)pyrid-3-yl] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 143395-98-6 [1S-[1α,2β,3β,4α(S*)]]-4-[7-[[1-[(3-chlorothien-2-yl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyrid-3-yl] N-ethyl 2,3-dihydroxycyclopentanecarboxamide 
• 280756-71-0 (R)-N-[1-[(3-chlorothien-2-yl)methyl]propyl]-N-(2-fluoro-3-nitropyrid-4-yl)-4-methylbenzenesulfonamide 

Relevant academic research and scientific papers

FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided c

Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators

The present invention relates to imidazo[5,4-c]pyridine or pyrrolo[3,2-c]pyridine compounds and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds, as well as pharmaceutical compositions containing at least one of these pyridine-based bicyclic compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pyridine-based bicyclic compounds are assumed to be modulators of the GRK5 protein, thereby regulating the expression and/or release of insulin and are useful for the treatment or prophylaxis of a metabolic disease and in particular for the treatment and prophylaxis of diabetes, obesity and impaired adipogenesis.

Process for preparing N6-substituted adenosine derivatives

This invention is directed to a process for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.

Process for preparing N6-substituted adenosine derivatives

The invention is directed to improved methods for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.